Over the last 12 months, Castle Biosciences insiders reported no purchases and 72 sales totaling $17.9M across SEC Form 4 filings. 92% of those filings were made under pre-arranged 10b5-1 trading plans.
Scroll the table sideways for price, value and marks.
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Sep 21, 2026 | MAETZOLD DEREK JPres. & Chief Exec. Officer · O·D | ▼ Sale | 5,916 | $35.33 | $209K | -38.3% | plan · 2 tranches · indirect |
| Sep 21, 2026 | MAETZOLD DEREK JPres. & Chief Exec. Officer · O·D | ▼ Sale | 8,580 | $35.33 | $303K | -28.5% | plan |
| Sep 15, 2026 | Juvenal Tobin WChief Commercial Officer · O | ▼ Sale | 6,600 | $33.73 | $223K | -10.1% | plan · 2 tranches |
| Sep 11, 2026 | MAETZOLD DEREK JPres. & Chief Exec. Officer · O·D | ▼ Sale | 5,934 | $32.02 | $190K | -32.6% | plan · 4 tranches · indirect |
| Sep 11, 2026 | MAETZOLD DEREK JPres. & Chief Exec. Officer · O·D | ▼ Sale | 8,584 | $32.02 | $275K | -28.6% | plan · 2 tranches |
| Sep 1, 2026 | Oelschlager Kristen MChief Operating Officer · O | ▼ Sale | 4,152 | $33.39 | $139K | -23.7% | plan · 2 tranches |
| Aug 31, 2026 | Juvenal Tobin WChief Commercial Officer · O | ▼ Sale | 1,730 | $32.81 | $57K | -2.6% | plan |
| Aug 28, 2026 | MAETZOLD DEREK JPres. & Chief Exec. Officer · O·D | ▼ Sale | 6,132 | $33.2 | $204K | -35.3% | plan · 12 tranches · indirect |
| Aug 28, 2026 | MAETZOLD DEREK JPres. & Chief Exec. Officer · O·D | ▼ Sale | 12,428 | $33.2 | $413K | -36.7% | plan · 2 tranches |
| Aug 25, 2026 | Juvenal Tobin WChief Commercial Officer · O | ▼ Sale | 9,050 | $35.04 | $317K | -11.9% | plan |
| Aug 25, 2026 | Oelschlager Kristen MChief Operating Officer · O | ▼ Sale | 24,602 | $34.06 | $838K | -25.3% | 3 tranches · indirect |
| Aug 17, 2026 | Juvenal Tobin WChief Commercial Officer · O | ▼ Sale | 1,730 | $29.59 | $51K | -2.2% | plan |
| Aug 14, 2026 | Stokes FrankChief Financial Officer · O | ▼ Sale | 24,908 | $29.77 | $742K | -41.5% | — |
| Aug 14, 2026 | MAETZOLD DEREK JPres. & Chief Exec. Officer · O·D | ▼ Sale | 6,132 | $30.02 | $184K | -34.7% | plan · 6 tranches · indirect |
| Aug 14, 2026 | MAETZOLD DEREK JPres. & Chief Exec. Officer · O·D | ▼ Sale | 1,100 | $30.02 | $33K | -4.9% | plan |
| Aug 5, 2026 | MAETZOLD DEREK JPres. & Chief Exec. Officer · O·D | ▼ Sale | 16,114 | $31.08 | $501K | -45.1% | plan · 6 tranches · indirect |
| Aug 5, 2026 | MAETZOLD DEREK JPres. & Chief Exec. Officer · O·D | ▼ Sale | 22,902 | $31.06 | $711K | -51.6% | plan · 3 tranches |
| Aug 3, 2026 | Oelschlager Kristen MChief Operating Officer · O | ▼ Sale | 8,586 | $29.77 | $256K | -39.3% | plan · 3 tranches |
| Aug 3, 2026 | Juvenal Tobin WChief Commercial Officer · O | ▼ Sale | 19,040 | $29.21 | $556K | -19.4% | plan · 4 tranches |
| Aug 3, 2026 | MAETZOLD DEREK JPres. & Chief Exec. Officer · O·D | ▼ Sale | 11,502 | $30.29 | $348K | -29.9% | plan · 4 tranches · indirect |
| Aug 3, 2026 | MAETZOLD DEREK JPres. & Chief Exec. Officer · O·D | ▼ Sale | 17,144 | $30.28 | $519K | -44.4% | plan · 2 tranches |
| Jul 27, 2026 | MAETZOLD DEREK JPres. & Chief Exec. Officer · O·D | ▼ Sale | 3,622 | $24.16 | $88K | -23.5% | plan · 12 tranches · indirect |
| Jul 27, 2026 | MAETZOLD DEREK JPres. & Chief Exec. Officer · O·D | ▼ Sale | 6,214 | $24.16 | $150K | -22.4% | plan · 2 tranches |
| Jul 14, 2026 | MAETZOLD DEREK JPres. & Chief Exec. Officer · O·D | ▼ Sale | 3,622 | $22.92 | $83K | -23.1% | plan · 6 tranches · indirect |
| Jul 14, 2026 | MAETZOLD DEREK JPres. & Chief Exec. Officer · O·D | ▼ Sale | 550 | $22.92 | $13K | -2.5% | plan |
| Jul 1, 2026 | MAETZOLD DEREK JPres. & Chief Exec. Officer · O·D | ▼ Sale | 3,622 | $24.29 | $88K | -22.7% | plan · 6 tranches · indirect |
| Jul 1, 2026 | MAETZOLD DEREK JPres. & Chief Exec. Officer · O·D | ▼ Sale | 6,214 | $24.29 | $151K | -22.4% | plan |
| Jul 1, 2026 | Oelschlager Kristen MChief Operating Officer · O | ▼ Sale | 8,586 | $24.42 | $210K | -28.2% | plan · 2 tranches |
| Jun 16, 2026 | Oelschlager Kristen MChief Operating Officer · O | ▼ Sale | 8,587 | $20.71 | $178K | -22% | plan |
| Jun 15, 2026 | MAETZOLD DEREK JPres. & Chief Exec. Officer · O·D | ▼ Sale | 3,622 | $20.66 | $75K | -22.3% | plan · 6 tranches · indirect |
| Jun 15, 2026 | MAETZOLD DEREK JPres. & Chief Exec. Officer · O·D | ▼ Sale | 550 | $20.66 | $11K | -2.5% | plan |
| Jun 1, 2026 | MAETZOLD DEREK JPres. & Chief Exec. Officer · O·D | ▼ Sale | 3,622 | $20.86 | $76K | -68.5% | plan · 6 tranches · indirect |
| Jun 1, 2026 | MAETZOLD DEREK JPres. & Chief Exec. Officer · O·D | ▼ Sale | 6,214 | $20.86 | $130K | -22.4% | plan |
| May 7, 2026 | MAETZOLD DEREK JPres. & Chief Exec. Officer · O·D | ▼ Sale | 3,622 | $22.15 | $80K | -62% | plan · 12 tranches · indirect |
| May 7, 2026 | MAETZOLD DEREK JPres. & Chief Exec. Officer · O·D | ▼ Sale | 6,214 | $22.15 | $138K | -22.4% | plan · 2 tranches |
| Apr 21, 2026 | MAETZOLD DEREK JPres. & Chief Exec. Officer · O·D | ▼ Sale | 3,622 | $25.1 | $91K | -59.1% | plan · 6 tranches · indirect |
| Apr 21, 2026 | MAETZOLD DEREK JPres. & Chief Exec. Officer · O·D | ▼ Sale | 550 | $25.1 | $14K | -2.5% | plan |
| Apr 6, 2026 | MAETZOLD DEREK JPres. & Chief Exec. Officer · O·D | ▼ Sale | 3,622 | $25.03 | $91K | -56.6% | plan · 6 tranches · indirect |
| Apr 6, 2026 | MAETZOLD DEREK JPres. & Chief Exec. Officer · O·D | ▼ Sale | 6,214 | $25.03 | $156K | -22.4% | plan |
| Mar 26, 2026 | MAETZOLD DEREK JPres. & Chief Exec. Officer · O·D | ▼ Sale | 3,622 | $25.55 | $93K | -54.2% | plan · 6 tranches · indirect |
| Mar 26, 2026 | MAETZOLD DEREK JPres. & Chief Exec. Officer · O·D | ▼ Sale | 550 | $25.55 | $14K | -2.5% | plan |
| Mar 18, 2026 | MAETZOLD DEREK JPres. & Chief Exec. Officer · O·D | ▼ Sale | 19,300 | $25.91 | $500K | -47.3% | plan · 2 tranches |
| Mar 16, 2026 | MAETZOLD DEREK JPres. & Chief Exec. Officer · O·D | ▼ Sale | 30,779 | $25.75 | $792K | -43% | plan · 3 tranches |
| Mar 12, 2026 | Juvenal Tobin WChief Commercial Officer · O | ▼ Sale | 20,863 | $25.24 | $527K | -19.4% | plan |
| Mar 12, 2026 | MAETZOLD DEREK JPres. & Chief Exec. Officer · O·D | ▼ Sale | 40,489 | $25.63 | $1.0M | -36.1% | plan · 2 tranches |
| Mar 11, 2026 | MAETZOLD DEREK JPres. & Chief Exec. Officer · O·D | ▼ Sale | 3,636 | $26.11 | $95K | -52.2% | plan · 6 tranches · indirect |
| Mar 5, 2026 | Stokes FrankChief Financial Officer · O | ▼ Sale | 6,001 | $27.98 | $168K | -9.1% | plan |
| Mar 5, 2026 | Cole G BradleyD | ▼ Sale | 7,403 | $28.47 | $211K | -27.7% | 2 tranches |
| Mar 3, 2026 | Stokes FrankChief Financial Officer · O | ▼ Sale | 7,000 | $27.44 | $192K | -11.8% | plan · 2 tranches |
| Feb 4, 2026 | MAETZOLD DEREK JPres. & Chief Exec. Officer · O·D | ▼ Sale | 4,017 | $39.52 | $159K | -4.6% | plan · 3 tranches |
The same Form 4 data over REST or MCP, already grouped into events with the plan flag and the dollar value read. A free key does 100 calls a day and needs no card. Prefer email? Castle Biosciences filings can reach your inbox instead.
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. This page shows open-market activity: purchases (code P), sales (S) and dispositions back to the issuer (D). Scheduled compensation events such as stock grants and option exercises are also filed on Form 4 but carry no trading signal, so they are not shown and counts here can be lower than the raw EDGAR filing total. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $CSTL feed.